Surrogate markers and joint models for longitudinal and survival data.
about
Sample size and power determination in joint modeling of longitudinal and survival dataEffects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer.The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogatFlexible stopping boundaries when changing primary endpoints after unblinded interim analyses.Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.Learning from clinical medicine to improve the use of surrogates in ecology
P2860
Surrogate markers and joint models for longitudinal and survival data.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Surrogate markers and joint models for longitudinal and survival data.
@ast
Surrogate markers and joint models for longitudinal and survival data.
@en
type
label
Surrogate markers and joint models for longitudinal and survival data.
@ast
Surrogate markers and joint models for longitudinal and survival data.
@en
prefLabel
Surrogate markers and joint models for longitudinal and survival data.
@ast
Surrogate markers and joint models for longitudinal and survival data.
@en
P1476
Surrogate markers and joint models for longitudinal and survival data.
@en
P2093
Jeremy M G Taylor
P304
P356
10.1016/S0197-2456(02)00234-9
P407
P577
2002-12-01T00:00:00Z